Alzheimer's Drug Discovery Foundation

The Alzheimer's Drug Discovery Foundation's mission is to rapidly accelerate the discovery and development of drugs to prevent, treat, and cure #Alzheimers.

[Alzheimer's Drug Discovery Foundation @TheADDF]

The ADDF has appointed Isobel Coleman as Chief Executive Officer.

A global leader across government, nonprofit & private sectors, she will guide the next era of Alzheimer’s research, advancing combination therapies & precision medicine.

Read more: https://t.co/KV0djByezO

[Alzheimer's Drug Discovery Foundation @TheADDF]

A recent @Barrons article featured insights from the ADDF's Laura Nisenbaum, who noted that Biogen's #CELIA results suggest "targeting tau can have both biological and clinical effects, which is exactly the kind of signal the field has been working on."
https://t.co/MxeXr7ZFXH

[Alzheimer's Drug Discovery Foundation @TheADDF]

Join the ADDF’s CEO Isobel Coleman for a live conversation about the organization’s next chapter, the momentum in Alzheimer’s research, and the potential for AI to accelerate innovation.

📅 June 3, 2026
🕧 12:30 pm ET

Register here: https://t.co/LlyPogDMwy

[Alzheimer's Drug Discovery Foundation @TheADDF]

@Roche received CE Mark approval for the Elecsys pTau217 blood test, developed with @EliLillyandCo & powered by ADDF-funded @AlZpath’s pTau217 antibody. The approval marks another important step toward broader access to scalable Alzheimer’s diagnostics. https://t.co/ZhgwXfEFfz

[Alzheimer's Drug Discovery Foundation @TheADDF]

New Phase 2 results from @biogen's CELIA study of #BIIB080 mark an encouraging step toward targeting Alzheimer’s beyond amyloid, reinforcing #tau as a promising target and highlighting momentum toward next-generation therapies.
https://t.co/rdTV9raPUn

[Alzheimer's Drug Discovery Foundation @TheADDF]

Today, #Fujirebio received CE Marking in the European Union for its ADDF-funded pTau217 test, following FDA approval in the U.S.

The milestone reflects growing global momentum behind scalable, validated biomarkers and a broader shift in the field.

https://t.co/5JKzXmxsgi

[Washington Lobbyist @TheWSHLobbyist]

The 16th annual Great Ladies Luncheon raised a record-breaking $850,000 for Alzheimer's research at The Ritz-Carlton DC. Read the full story on The Washington Lobbyist: https://t.co/jCO6xm23Ao #DCFashionEvents #ADDFLadiesLuncheon @TheADDF #GreatLadiesLuncheon #BrainHealth

[Feixiong Cheng @FeixiongCheng]

Alzheimer's disease drug development pipeline: 2026 published today! The 2026 AD drug development pipeline includes 158 unique therapies in 192 trials, marking continued growth in disease-modifying agents, with 35% being repurposed drugs. Thanks @DrJeffCummings @NIHAging @TheADDF

[Alzheimer's Drug Discovery Foundation @TheADDF]

The Alzheimer’s Drug Development Pipeline 2026 Report reveals that treating the underlying biology is driving the next gen of therapies—75% of drugs target novel aging pathways, paving the way for combination therapy & precision medicine. @DrJeffCummings
https://t.co/xafzySduoS

[Alzheimer's Drug Discovery Foundation @TheADDF]

“Clean” nicotine is being marketed as a brain boost.

ADDF’s Yuko Hara shares with @AARP that questions remain about safety and addiction potential. While nicotine may offer short-term cognitive effects, it also comes with risks.

https://t.co/OYxtId9IdC

[Alzheimer's Drug Discovery Foundation @TheADDF]

Exercise, nutrition & social engagement are core components of supporting cognitive health in aging populations. The future lies in precision prevention, integrating lifestyle & therapeutic interventions tailored to each person, similar to heart disease. https://t.co/xhvwoSyhBx

[Phyllis Ferrell @PhylFerrell]

Dinner with the new @TheADDF CEO, what a fantastic lady, and Jane McIntosh, who are a star!

[Phyllis Ferrell @PhylFerrell]

Is there anything much better than doing meaningful work with amazing friends? Not sure…

Thank you to Heidi McWilliams’ #OpensMinds and the @TheADDF for hosting us in #PalmBeach, proud to be members of the board!

@MiiaKivipelto
#brainhealth

[Washington Lobbyist @TheWSHLobbyist]

DC's most glamorous Alzheimer's fundraiser is back — the ADDF's Great Ladies Luncheon and Fashion Show returns May 5. 🔗https://t.co/h0QOZGO2ic
#AlzheimersResearch #GreatLadiesLuncheon #WashingtonDC #HilarityForCharity #ADDF @TheADDF

[Alzheimer's Drug Discovery Foundation @TheADDF]

A new analysis is challenging the impact of anti-amyloid treatments, pointing to limited cognitive benefit and potential risks. As Laura Nisenbaum, ADDF's Executive Director of Drug Development, noted to @AARP, “Not all drugs in this class are the same.” https://t.co/hMT0EPMS9q

[Alzheimer's Drug Discovery Foundation @TheADDF]

More than 85% say they would take an Alzheimer’s blood test if recommended by their physician, according to a study in Alzheimer’s & Dementia. The ADDF has helped drive this progress through our DxA, bringing the first generation of blood tests to market.🔗https://t.co/FOVqzv2u8L

[Alzheimer's Drug Discovery Foundation @TheADDF]

Solving Alzheimer’s is a new Substack from the Alzheimer’s Policy Working Group, featuring insights from frontline clinicians.

At the ADDF’s DxA, we’re advancing blood tests and digital tools designed for use in primary care to enable early diagnosis. https://t.co/SX68MljlI0

[Alzheimer's Drug Discovery Foundation @TheADDF]

Gene therapy is a promising yet complex area of research. At the ADDF, we have long considered ApoE4 a critical target. Now, with growing momentum across the field, there is renewed interest in novel gene therapy strategies aimed at addressing it directly. https://t.co/0dOIrBMZdu

[Miles Berger @RealMilesBerger]

So, what did MARBLE show? Was CN-105 safe to give to older surgical patients & did it prevent delirium? Stay tuned for the results tomorrow in @JAMANetworkOpen @TheADDF @NIH @ASALifeline @APSForg @snaccprez @SNACCNeuro @Duke_Anesthesia @stanfordanes @AmerDelirium @PeriopCognPIA

[Alzheimer's Drug Discovery Foundation @TheADDF]

Aaron Burstein, ADDF Head of Search & Evaluation, shared with @biospace, how biomarker advances are strengthening the link between biology and clinical outcomes and guiding more targeted treatment decisions.
Read More: https://t.co/9axKvZGh11

[Alzheimer's Drug Discovery Foundation @TheADDF]

Exciting news from @AviadoBio, announcing the ADDF and @AFTDHope strategic investment to advance AVB-101, an investigational gene therapy for people living with #FTD-GRN, and enrollment underway for the fourth cohort of the Phase 1/2 ASPIRE-FTD trial.

[AviadoBio @AviadoBio]

We’re pleased to announce AviadoBio initiated enrollment for the fourth cohort of our Phase 1/2 ASPIRE-FTD trial evaluating AVB-101 in FTD-GRN and shared encouraging early biomarker and safety data.

Read more here: https://t.co/5zt6dsPBCD